OUR RESOURCES
Video and slides 
CRSF Asco list of publications 
Ongoing studies 5th Master Class in Lung Cancer
Early Lung Cancer - Immunotherapy: Stage 4 Non Driver Mutated PDL1 Positive - 22 July 2022
Interpretation Of PD1 1 MSI TMB In NSCLC
Selection Of 1st Line Immunotherapy Pdl1 > 50% & 1% In NSCLC
Early Lung Cancer - Immunotherapy: Stage 4 Non Driver Mutated PDL1 Positive - 22 July 2022
Interpretation Of PD1 1 MSI TMB In NSCLC
Selection Of 1st Line Immunotherapy Pdl1 > 50% & 1% In NSCLC